Julia Petraitis
Medical · Marion, OHNPI 1295108363
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.2% of the total across 469 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 39 manufacturers reported payments, led by AbbVie at 28.4% of the total. Among medical clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 469 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Teva Pharmaceuticals USA, Inc.$1K
- Biohaven Pharmaceuticals, Inc.$922
- Vanda Pharmaceuticals Inc.$516
- Neurocrine Biosciences, Inc.$505
- Lundbeck LLC$401
- plus $3K from 33 others
What the payments were for
- Consulting fees$8009%
- Food & beverage$8,13390%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$800
- Trudhesa$114
How this compares
$9,018 in reported general payments places this provider in the 95th percentile of 547 medical providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 24 | $40,020 |
| Buprenorphine | 128 | $39,088 |
| VraylarCariprazine Hcl | 17 | $36,135 |
| BelbucaBuprenorphine Hcl | 33 | $25,357 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 187 | $24,261 |
| UbrelvyUbrogepant | 11 | $17,680 |
| QuliptaAtogepant | 18 | $16,923 |
| Emgality PenGalcanezumab-Gnlm | 15 | $13,019 |
| TrintellixVortioxetine Hydrobromide | 13 | $7,237 |
| Celecoxib | 82 | $5,446 |
| Fluoxetine Hcl | 12 | $3,733 |
| Tizanidine Hcl | 88 | $2,677 |
| Pregabalin | 95 | $1,998 |
| Gabapentin | 166 | $1,989 |
| Ondansetron Hcl | 19 | $1,697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Ubrelvy, Qulipta | $2,560 | $70,73846 claims |
| PfizerNurtec Odt | $121 | $40,02024 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $107 | $25,35733 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $143 | $7,23713 claims |
| Almatica Pharma LLCSertraline Hcl | $41 | $84379 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 547 medical providers in Ohio.
Other medical in Marion
- Shannon GhizzoniColumbus$116K
- Susan WhittCanal Winchester$74K
- Christopher FrickLima$46K
- Kodi VealeAkron$43K
- Abbey BlairCleveland$24K
- Joana ZulaConcord Twp$23K
- Chelsea AustenColumbus$21K
- Kristen FairchildToledo$19K
- Kaitlin SchuppGahanna$17K
- Melanie HunglerCincinnati$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.